RYBREVANT® Plus Lazertinib Shows Significant PFS Improvement in EGFR-Mutated NSCLC
Key Insights
The Phase 3 MARIPOSA study demonstrated that RYBREVANT® (amivantamab-vmjw) plus lazertinib significantly improved progression-free survival (PFS) compared to osimertinib in first-line EGFR (search)-mutated NSCLC patients.
The combination therapy's safety profile was consistent with previous data, indicating manageable adverse events in the treated population.
An interim overall survival (OS) analysis showed a trend favoring the RYBREVANT® plus lazertinib combination, with ongoing monitoring to determine statistical significance.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from the Phase 3 MARIPOSA study, evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib versus osimertinib as a first-line treatment for patients with locally advanced or metastatic EGFR (search)-mutated non-small cell lung cancer (search) (NSCLC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients receiving the combination therapy compared to those receiving osimertinib alone.
Key Findings from the MARIPOSA Study
The MARIPOSA study is a pivotal Phase 3 trial designed to assess the efficacy and safety of RYBREVANT®, a bispecific antibody targeting epidermal growth factor receptor (EGFR (search)) and mesenchymal-epithelial transition (MET), when combined with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI). The trial enrolled patients with locally advanced or metastatic EGFR-mutated NSCLC who had not previously received systemic therapy for advanced disease.
The results indicated that the combination of RYBREVANT® and lazertinib led to a significant improvement in PFS compared to osimertinib. The safety profile of the combination was consistent with previously reported data, suggesting that the adverse events were manageable. An interim analysis of overall survival (OS) showed a trend favoring the combination therapy, and patients will continue to be followed for subsequent OS analyses to determine the statistical and clinical significance.
Implications for NSCLC Treatment
Lung cancer remains a leading cause of cancer-related deaths worldwide, with NSCLC accounting for the majority of cases. EGFR (search) mutations are common in NSCLC, particularly among certain populations. Osimertinib is a standard first-line treatment for patients with EGFR-mutated NSCLC; however, resistance to EGFR TKIs often develops, leading to disease progression. The MARIPOSA study suggests that the combination of RYBREVANT® and lazertinib could offer a new first-line treatment option for these patients, potentially delaying disease progression and improving outcomes.
The detailed data from the MARIPOSA study will be presented at an upcoming medical meeting and submitted to regulatory authorities for review. If approved, this combination therapy could represent a significant advance in the treatment of EGFR (search)-mutated NSCLC.